NCT06790797Recruiting
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
Investigating the Biomarkers in Tumor Microenvironment and Peripheral Blood Microenvironment to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
Source: ClinicalTrials.gov · Last updated 24 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients. To do so, the investigators plan to collect tumor tissue and peripheral blood samples before and after immunotherapy, and use single-cell RNA sequencing, Multiplex immunohistochemistry, and flow cytometry. The investigators will analyze changes in the proportion of cancer cell-specific T-cell subpopulations related to treatment response before and after therapy, and seek biological markers that can predict the efficacy of immunotherapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 18 Jan 2025
- Start date
- Feb 2023
- Primary completion date
- Jul 2027
- Lead sponsor
- Zhao Jun
- Diseases
- Lung cancer, Gastric and esophageal cancer
- NCT number
- NCT06790797
What you commit to
- Study type: Observational
- Planned participants: 50
- From Feb 2023 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
Other illness
- Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
- Poor vascular conditions.
- Patients with hematogenic infectious diseases, such as HBV.
- Patients with psychiatric disorders or severe mental illnesses.
Other
- Patients with tumor emergencies that require immediate treatment.
- Patients who have difficulty communicating or are unable to be followed up for a long time.
- Other situations that are not suitable for inclusion in the study.
Who the study is looking for
- Patients with a pathological diagnosis of lung cancer or esophageal cancer who have agreed to receive PD-1/PD-L1 antibody immunotherapy;
- Age between 18 and 80 years old;
- ECOG PS score of 0 or 1;
- Adequate organ and bone marrow function;
- Anticipated survival time of at least 12 weeks;
- Willing and able to provide written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Soochow University Coordinator of this site? Confirm its status | Suzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.